文献速递妇科生殖医学

结合代谢组学与机器学习模型作为无需促肾上腺皮质激素检测即可区分非经典型21-羟化酶缺陷症与多囊卵巢综合征的工具

Combining metabolomics and machine learning models as a tool to distinguish non-classic 21-hydroxylase deficiency from polycystic ovary syndrome without adrenocorticotropic hormone testing.
PubMed 文献 · Hum Reprod · 2023-01-01

该双中心研究以19例非经典型21-羟化酶缺陷症(NC21OHD)和19例对照为内部训练集建模,在由17例NC21OHD、72例对照和266例多囊卵巢综合征(PCOS)患者组成的外部测试集中验证,基于单次采样的15种类固醇谱模型以100%敏感度和特异度区分NC21OHD与PCOS,无需ACTH兴奋试验;但队列有限且需更大前瞻性研究验证。

要点

  • 单次采样的15种类固醇谱机器学习模型可区分NC21OHD与PCOS,敏感度和特异度均为100%。
  • 模型在月经周期任意时相采样均不影响判别效率,无需ACTH兴奋试验。
  • 模型优于当前参考策略,可减少ACTH试验使用,但需更大前瞻性研究验证。

核心结论

  • 单次采样结合代谢组学与机器学习模型或可作为动态ACTH试验的替代,用于在任何月经周期时相排除临床高雄激素表现者的NC21OHD诊断。

研究设计与样本

  • 双中心招募:内部训练集含19例NC21OHD和19例对照用于建模;测试集含17例NC21OHD、72例对照和266例PCOS患者用于评估诊断策略性能。
  • 采用液相色谱-串联质谱(LC-MS/MS)测定血清中15种类固醇,作为映射类固醇生物合成途径的模型输入。

主要发现

  • 基于基线LC-MS/MS类固醇指纹构建的模型在最初549例女性的外部测试队列中,从266例PCOS中成功排除全部17例NC21OHD,敏感度和特异度均为100%,未使用ACTH试验。
  • 月经周期时相不影响模型效率。

关键数值与推荐

  • 模型在外部测试队列中区分NC21OHD与PCOS的敏感度和特异度均为100%。
  • 原文未报告具体的类固醇阈值、剂量或推荐等级。

临床怎么用

  • 作者认为该工具可为高雄激素管理提出新的症候学,模型诊断性能优于当前参考策略,限制ACTH试验使用可能便于患者管理。
  • 作者指出模型稳健性需通过更大前瞻性研究在临床实践中最终验证。

局限性

  • 主要局限性为使用了有限且完全前瞻性的队列。
  • 分析学问题:并非所有实验室均配备能常规检测这15种类固醇的质谱仪。
  • 模型稳健性需通过更大前瞻性研究在临床实践中最终验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can a combination of metabolomic signature and machine learning (ML) models distinguish nonclassic 21-hydroxylase deficiency (NC21OHD) from polycystic ovary syndrome (PCOS) without adrenocorticotrophic hormone (ACTH) testing? SUMMARY ANSWER: A single sampling methodology may be an alternative to the dynamic ACTH test in order to exclude the diagnosis of NC21OHD in the presence of a clinical hyperandrogenic presentation at any time of the menstrual cycle. WHAT IS KNOWN ALREADY: The clinical presentation of patients with NC21OHD is similar with that for other disorders of androgen excess. Currently, cosyntropin stimulation remains the gold standard diagnosis of NC21OHD. STUDY DESIGN, SIZE, DURATION: The study was designed using a bicentric recruitment: an internal training set included 19 women with NC21OHD and 19 controls used for developing the model; a test set included 17 NC21OHD, 72 controls and 266 PCOS patients used to evaluate the performance of the diagnostic strategy thanks to an ML approach. PARTICIPANTS/MATERIALS, SETTING, METHODS: Fifteen steroid species were measured in serum by liquid chromatography-mass spectrometry (LC-MS/MS). This set of 15 steroids (defined as 'steroidome') used to map the steroid biosynthesis pathway was the input for our models. MAIN RESULTS AND THE ROLE OF CHANCE: From a single sample, modeling involving metabolic pathway mapping by profiling 15 circulating steroids allowed us to identify perfectly NC21OHD from a confounding PCOS population. The constructed model using baseline LC-MS/MS-acquired steroid fingerprinting successfully excluded all 17 NC21OHDs (sensitivity and specificity of 100%) from 266 PCOS from an external testing cohort of originally 549 women, without the use of ACTH testing. Blood sampling timing during the menstrual cycle phase did not impact the efficiency of our model. LIMITATIONS, REASONS FOR CAUTION: The main limitations were the use of a restricted and fully prospective cohort as well as an analytical issue, as not all laboratories are equipped with mass spectrometers able to routinely measure this panel of 15 steroids. Moreover, the robustness of our model needs to be established with a larger prospective study for definitive validation in clinical practice. WIDER IMPLICATIONS OF THE FINDINGS: This tool makes it possible to propose a new semiology for the management of hyperandrogenism. The model presents better diagnostic performances compared to the current reference strategy. The management of patients may be facilitated by limiting the use of ACTH tests. Finally, the modeling process allows a classification of steroid contributions to rationalize the biomarker approach and highlight some underlying pathophysiological mechanisms. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by 'Agence Française de Lutte contre le dopage' and DIM Région Ile de France. This study was supported by the French institutional PHRC 2010-AOR10032 funding source and APHP. All authors declare no competing financial interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Bachelot G, Bachelot A, Bonnier M, et al. Combining metabolomics and machine learning models as a tool to distinguish non-classic 21-hydroxylase deficiency from polycystic ovary syndrome without adrenocorticotropic hormone testing. Hum Reprod. 2023. PMID: 36427016. doi:10.1093/humrep/deac254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。